Shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) have earned an average recommendation of “Hold” from the twenty-four brokerages that are presently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have given a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $11.43.

Several research firms have recently issued reports on ENDP. Guggenheim began coverage on shares of Endo International in a research report on Tuesday. They set a “neutral” rating and a $8.50 price objective on the stock. ValuEngine upgraded shares of Endo International from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. BidaskClub upgraded shares of Endo International from a “sell” rating to a “hold” rating in a research report on Tuesday. Cantor Fitzgerald reduced their price objective on shares of Endo International from $9.00 to $7.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. Finally, Zacks Investment Research upgraded shares of Endo International from a “strong sell” rating to a “hold” rating in a research report on Monday, September 25th.

Endo International (NASDAQ ENDP) remained flat at $$7.81 during trading on Monday. 3,881,863 shares of the company traded hands, compared to its average volume of 7,082,444. The stock has a market cap of $1,740.00, a P/E ratio of 1.63, a PEG ratio of 2.15 and a beta of 0.59. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86. Endo International has a one year low of $5.77 and a one year high of $17.99.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.06. The firm had revenue of $786.90 million for the quarter, compared to analysts’ expectations of $794.93 million. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The company’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.01 earnings per share. sell-side analysts expect that Endo International will post 3.67 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of ENDP. Cornerstone Capital Management Holdings LLC. boosted its stake in Endo International by 64.0% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 135,627 shares of the company’s stock worth $1,160,000 after buying an additional 52,927 shares during the period. LMR Partners LLP purchased a new position in Endo International during the third quarter worth $148,000. Van ECK Associates Corp boosted its stake in Endo International by 67.1% during the third quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock worth $2,921,000 after buying an additional 136,873 shares during the period. Alps Advisors Inc. boosted its stake in Endo International by 9.3% during the third quarter. Alps Advisors Inc. now owns 250,511 shares of the company’s stock worth $2,146,000 after buying an additional 21,373 shares during the period. Finally, Gamco Investors INC. ET AL boosted its stake in Endo International by 76.2% during the third quarter. Gamco Investors INC. ET AL now owns 110,500 shares of the company’s stock worth $946,000 after buying an additional 47,800 shares during the period. 93.17% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/12/15/analysts-set-endo-international-plc-endp-price-target-at-11-65.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Stock Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related stocks with our FREE daily email newsletter.